A Jesuit, Filipino, and Asian Ecclesiastical Faculty of Theology

Wednesday, April 26, 2017
Text Size

ELIZABETH RONDAIN, M.D.
Lecturer, Assistant Professor of
Family Ministries and Pastoral Counseling

Contact Information

Center for Family Ministries
Ateneo de Manila University
Loyola Heights, Quezon City
Tel. (+63 02) 426-4289 to 92

Course

Assessment and Initial Intervention of Individual and Relationship Disorders

Education

Bachelor of Science, Major in Biology, University of the Philippines, Quezon City
Doctor of Medicine, University of the East Ramon Magsaysay Memorial Medical Center, Manila
Post-Graduate Internship, Makati Medical Center, Makati City
Residency in Psychiatry, Makati Medical Center, Makati City

Professional Activities

Vice-Chair and Training Officer of the Department of Neuroscience, Section of Psychiatry, and Active Consultant, Makati Medical Center, Makati City
Visiting Consultant, The Medical City, Pasig City
Consultant Psychiatrist, Center for Family Ministries, Quezon City
Member, Counseling Training Team, Jesuit Conference for East Asia and Oceania, Quezon City
Diplomate, Philippine Board of Psychiatry
Fellow, Philippine Psychiatric Association
Member, Makati Medical Society

Experiences in Clinical Trials

Principal Investigator, Iloperidone Phase III Study in Schizophrenic Patients ILPIII 3002. A Prospective Randomized Multi-Center, Double-Blind, Flexible Dose, Parallel Group Study of the Efficacy and Safety of Iloperidone Treatment: (Dose Range 4–16 mg/day BID as compared with Haloperidol 5–25 mg/day given Daily), 1999 – 2000.

Principal Investigator, Ziprasidone Intramuscular/Oral in the Treatment of Acute Exacerbation of Schizophrenic and Schizoaffective Disorder: A 4-week Open Administration Study, 2001 – 2002.

Co-Investigator, Acute Depression Study/PNOS, 2002 – 2003.

Principal Investigator, Lundbeck Study 99824. “Sertindole versus Risperidone Safety Outcome Study: A Randomized, Partially Blinded, Parallel-Group, Active Controlled Study”, October 2004 to April 2008.

Principal Investigator, Lundbeck Study 10200. “A Six-Month Double Blind, Risperidone-Referenced, Flexible-Dose, Parallel-Group Extension Study of Bifeprunox in Patients with Schizophrenia”, 2004 to 2006.

Principal Investigator, Organon and Pfizer, Inc. Study:
 
A7501004. “A Phase III Randomized Placebo-Controlled, Double Blinded Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs Olanzapine and Placebo in Patients with an Acute Mania Episode”.

A7501006. “A Double Blind 9-Week Extension Study Evaluating the Safety and Maintenance of Effect of Asenapine vs Olanzapine in the Treatment of Subjects with Acute Mania”.

A7501007. “A Double Blind 40-Week Continuation Study Evaluating the Safety and Maintenance of Effect of Asenapine vs Olanzapine in the Treatment of Subjects with Acute Mania”, January 2005 – March 2007.

Principal Investigator, Janssen Study R076477SCH3024. “An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER In Subjects with Schizophrenia”, October 2007 to May 2008.

Co-Investigator, Lilly Study F1J-MC-B019. “A Prospective, Observational Study Comparing the Frequency of Treatment-Emergent Sexual Dysfunction over 8 Weeks in Patients with Major Depressive Disorder Treated with Either Duloxetine Hydrochloride or a Selective Serotonin Reuptake Inhibitor Antidepressants and Evaluated for 6 Months”, February 2008 to present.

Principal Investigator, Organon and Quintiles Inc. Study A7501021. “A Randomized Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability and Pharmacogenetics of Asenapine in Elderly Subjects with Psychosis”, August 2008 to March 2009.

Principal Investigator, Dainippon Sumitomo Pharma Study  D1050231. “A Phase 3 Randomized, Placebo- and Active Comparator – Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia”, Ongoing from December 2008.